Study title: Assessment of the therapeutic efficacy and safety of mizolastine in the treatment of chronic idiopathic urticaria. Open-label study of increasing doses (5-10-20mg per day in 2 divided doses) (URTIOC study). -Sayag J. Tudor D. Demontrond V. Narbonne G. Ben-soussen P.- 05/05/1993
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases [C20] | |||||
Brands: Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: MIZOLASTINE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: M.34.02.92.005 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |